For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.
Regulatory context
Regulatory context; not efficacy evidence
No matched controlled human study of this exact commercial preparation was verified.
Reported findings. Background context only. Matched evidence for the exact marketed formulation is not established by this reference.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Evidence and toxicology must match the exact sequence; PNC-27 cell results cannot establish PNC-28 clinical efficacy.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Lab or animal research
PNC-28: pancreatic cancer cell experiments (2008)
Human pancreatic cancer cell models, not treated human patients.
Reported findings. Researchers studied pancreatic cancer cell responses to PNC-28.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Cell findings do not establish clinical antitumor benefit. PNC-28 is distinct from PNC-27 and exact commercial identity remains unverified.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-10. Clinician review pending.
Lab or animal research
PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo.
Rat pancreatic carcinoma implants in nude mice, not treated human patients.
Reported findings. Tumor suppression varied with delivery conditions, including blockade during continuous administration.
Nonresponse. Remotely treated tumors regrew after delivery ended; lower-exposure established-tumor groups lacked significant growth-rate separation from controls.
Harms. Weight and behavior appeared preserved, but hematology and liver-function toxicity were not tested.
Limits. Original full paper reviewed at https://stacks.cdc.gov/view/cdc/192136/cdc_192136_DS1.pdf; animal findings do not establish human antitumor benefit or commercial-product equivalence.
Preparation: Experimental p53 residues 17–26 with C-terminal penetratin; exact commercial sequence and preparation unverified. Route: Continuous subcutaneous or intraperitoneal osmotic pumps in nude mice
Read original source ↗Editorial review 2026-10-10. Clinician review pending.